Available evidence does not indicate that treatments approved for people with Alzheimer’s disease can improve cognitive function in people with Huntington’s disease, according to a review study. “The existing literature does not provide sufficient evidence to support the use of cholinesterase inhibitors or memantine for managing cognitive symptoms in…
News
The Hereditary Disease Foundation (HDF), committed to advancing research on Huntington’s disease (HD) and potential treatments, has changed its name to Huntington’s Disease Foundation. “This name change is more than symbolic — it is a powerful reaffirmation of our purpose,” Meghan Donaldson, Huntington’s Disease Foundation CEO, said in…
uniQure’s experimental gene therapy AMT-130 safely and effectively slows the progression of Huntington’s disease, according to top-line, three-year data from two Phase 1/2 clinical trials. At 36 months, the use of high-dose AMT-130 was shown to slow Huntington’s progression by 75% — results the developer called “statistically significant”…
Three months of daily treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 safely and effectively reduced blood levels of Huntington’s disease-associated proteins in people with the neurodegenerative condition. That’s according to interim results from a substudy of a Phase 1 clinical trial that specifically showed a greater reduction with…
Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements as a method to track Huntington’s disease activity in clinical trials. The CHDI Foundation is a nonprofit biomedical research organization dedicated to advancing new therapies that can slow the…
Pridopidine may safely and effectively slow Huntington’s disease progression in patients who aren’t taking antidopaminergic medications, which are commonly used for psychiatric symptoms and chorea, or involuntary movements. That’s according to full results from the Phase 3 PROOF-HD clinical trial (NCT04556656), which tested pridopidine against a…
Swallowing difficulties start in the early stages of Huntington’s disease (HD) and progress over time, affecting both voluntary movements in the mouth and involuntary movements that transport food to the stomach while protecting the airway, a study showed. Researchers used the Swallowing Disturbance Questionnaire (SDQ) to assess swallowing problems,…
An investigational treatment prepared from stem cells found in young teeth appears to be safe and to help adults with Huntington’s disease move better and carry out daily tasks more easily, perhaps by slowing damage to the brain, according to data from a Phase 2 clinical trial. Called…
A postdoctoral researcher at the University of Michigan won a three-year grant to support her work investigating the cellular mechanisms underlying Huntington’s disease. The Huntington’s Disease Society of America (HDSA) awarded its Berman-Topper Family HD Career Development Fellowship to Elizabeth Tidwell, PhD, whose project, “Determining the structure…
Neurodegeneration of the pathways that help relay information from the cerebellum — a brain area involved in motor and cognitive functions — is associated with worsening motor and cognitive symptoms in people with Huntington’s disease, a study reported. Tracking changes in these pathways, or tracts, may help researchers follow…
Recent Posts
- Faulty cellular waste disposal system may drive Huntington’s: Study
- What the holidays mean when living with Huntington’s disease
- $12M grant will back first trial of stem cell therapy for Huntington’s
- A tribute to the kindness of strangers in life with Huntington’s
- How to support someone who is planning for future care
- Antipsychotics improve functional capacity, independence in HD
- Despite dwindling resources, hope endures among researchers
- The ‘invisible’ symptoms of Huntington’s that people don’t see
- Genetic variant delays Huntington’s onset by up to 23 years: Study
- Watching Huntington’s switch roles in our marriage was jarring